Novavax Announces Release Date of 2006 Fourth Quarter, Full Year Financial Results and Investor Conference Call
ROCKVILLE, Md., March 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2006 fourth quarter and full-year financial results in a press release to be issued after 7:00 a.m. Eastern Time on March 14, 2007. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. Eastern Time on March 14. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is 1 (800) 811 8824 (International: (913) 981 4903).
A live audio webcast of the conference call will be available at www.novavax.com under Investors/Events. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days starting on March 14 at www.novavax.com. A replay of the conference call will also be available by telephone beginning March 14 at noon. To access the replay, dial 1 (888) 203 1112 and enter pass code 3056084.
About Novavax, Inc.
Novavax, Inc. is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.
SOURCE Novavax, Inc.
CONTACT: Mariann Caprino of Novavax, Inc.,